ABOUT US
We are Pharmaceutical R&D consultancy firm started in 2016. The prime objective of Adex is to resolve complex issues in the Pharmaceutical development of New drugs (INDS) and life cycle management of approved drugs (NDAs/ANDAs).
Adex is headed by Dr. Yogeshwar Bachhav, who after finishing PhD in Pharmaceutics from the Institute of Chemical Technology, Mumbai (Formerly UDCT) worked in Europe (DACH region) for more than 14 years with different start up and mid-size biotech/pharmaceutical companies. During this tenure, he has successfully managed pharmaceutical development of several projects from POC to phase 1, 2 and 3 clinical trials. He has Strong network of Experts and CROs/CMOs in EU, USA and Australia. In addition, he has 16 international publications, 8 patents and 26 conference proceedings to his credit. And recently he has edited a book for Wiley-VCH (Germany) on “Innovative Dosage Form, Design and Development at Early Stage”.
Dr. Yogeshwar Bachhav
Dr. Yogeshwar Bachhav is Pharmacist by training, after finishing PhD in Pharmaceutics from the Institute of Chemical Technology; Mumbai (Formerly UDCT) worked in Europe (Switzerland and Germany) for around 15 years with different start up and mid-size biotech/pharmaceutical companies.
He is associated with a German Biotech AiCuris Anti-infectives Cures GmBH Wuppertal Germany from 2014 and his responsibility is to deal with Pharmaceutical development of new drugs in anti-infectives segment. He turned as full-time consultant to AiCuris from 2015 onwards.
He founded a Pharmaceutical R&D consultancy firm – Adex Pharma in 2016. The prime objective of Adex is to resolve complex issues in the Pharmaceutical development of New drugs (INDS) and life cycle management of approved drugs (NDAs/ANDAs).
Research Publications
Published several international research articles covering various aspects of novel
drug delivery platforms for small molecules &/or peptides for oral, dermal and
parenteral applications
• 16+ International Publications & Edited two books: “Innovative Dosage Form,
Design” and “Development at Early Stage” for Wiley-VCH (Germany)